Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Greetings, and welcome to the INmune Bio Second Quarter 2025 Earnings Call. [Operator Instructions] As a reminder, this conference is being ...

Company to Host Conference Call Today, August 7th, at 4:30pm ETBOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company ...

INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference BOCA RATON, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a ...

Explore INmune Bio's Fair Values from the Community and select yours. Even when a business is losing money, it's possible for shareholders to make money if they buy a good busines ...

Explore INmune Bio's Q2 2025 earnings call: new CEO, strategic shifts, XPro's Alzheimer's pause, CORDStrom advancements, and a focus on partnerships.

Pre-earnings options volume in INmune Bio (INMB) is normal with calls leading puts 10:7. Implied volatility suggests the market is anticipating a ...

When INmune Bio last reported its balance sheet in December 2019, it had zero debt and cash worth US$7.0m. Importantly, its cash burn was US$5.4m over the trailing twelve months.

Inmune Bio, Inc., headquartered in Boca Raton, Florida, operates in the biological products industry, focusing on innovative therapies in the field of immunology.

INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where INmune Bio, Inc. (NASDAQ:INMB) stands against ...

See disclosure here or remove ads. INmune Bio plans to further assess the long-term benefits of CORDStrom, including wound healing and closure, in a 12-month open-label extension (OLE) study.

INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer, today announces that company president and ...